Clinical trial · Interventional
Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma
Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Metastatic Choroidal Melanoma
NCT01334008CI-TRIAL-00097857completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Circulating tumor DNA detection and quantification in patients with metastatic choroidal melanoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Choroidal Melanoma, Diffuse | Choroid Melanoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Blood sampling
- interventionNames
- Biological: Blood sampling
Primary outcomes (1)
- measure
- Assessment and development of circulating tumor DNA detection techniques
- timeFrame
- 2 years
- description
- Quantification of circulating tumor DNA in blood samples. Results expressed in number of samples where circulating DNA is present.
Secondary outcomes (1)
- measure
- Detection technique comparison (PAP (pyrophosphorolysis activated polymerisation), BEAMing, NGS(next sequencing generation)) in terms of feasibility, robustness, sensitivity and cost.
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> or = 18 years. * Patient with a metastatic choroidal melanoma. * Patient with tumor or metastasis available for GNAQ (Guanine nucleotide blinding protein) status characterization. * Patient able to stand a blood collection. * Signed written informed consent approved by competent authority and ethic committee. Exclusion Criteria: * Patient without social protection/insurance. * Current pregnancy and lactation. * All social, medical, psychological, situations making the study impossible. * Person deprived of liberty.
References
Publications (1)
- RESULTBidard FC, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, Cassoux N, Desjardins L, Milder M, Vaucher I, Pierga JY, Lebofsky R, Stern MH, Lantz O. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer. 2014 Mar 1;134(5):1207-13. doi: 10.1002/ijc.28436. Epub 2013 Sep 3. PMID 23934701